Nanoscope Leadership Prepares for Advanced Therapies USA 2026 in Boston
Biotechnology firm Nanoscope Therapeutics announced that members of its leadership team will take the stage at Advanced Therapies USA 2026, scheduled for November 4–5 at the Hynes Convention Center in Boston. Bringing together manufacturers, investors, commercial leaders, and developers of cell and gene therapies, the conference focuses on overcoming the hurdles of moving cutting-edge treatments from clinical settings to patients.
The company’s leadership team plans to outline the scientific, regulatory, commercial, and market access pathways for MOGENRY, also known as sonpiretigene isteparvovec or MCO-010. This investigational, one-time, in-office, mutation-agnostic, optogenetic gene therapy is currently under FDA and PMDA review.
Executives Speak at Upcoming Conference Sessions
Events begin on Wednesday, November 4, 2026. Co-founder and Chief Executive Officer Sulagna Bhattacharya will join a keynote panel titled “Navigating the Cell and Gene Therapy Landscape: Opportunities & Challenges for Driving Market Success.” Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, will moderate the discussion at 9:45 AM ET in Keynote/Theatre 1.
Later that morning at 11:30 AM ET in Hall D, Level 2, Co-founder, President, and Chief Scientific Officer Samarendra Mohanty will deliver a presentation on disease-agnostic gene therapy for neurodegenerative conditions within Track 4. The scientific focus shifts to market economics in the afternoon when Executive Vice President of Value & Access Ramesh Arjunji presents on building early evidence to support access and pricing for rare diseases at 1:55 PM ET in Room 209. Arjunji will also join a 5:10 PM ET panel in the same room on overcoming barriers and expanding access to cell and gene therapies, moderated by former PRO/PE Regulatory Review Officer, FDA, Nneka Onwudiwe.
The second day of the conference features additional executive appearances. Samarendra Mohanty will appear on Thursday, November 5, at 9:35 AM ET for a keynote panel in Keynote/Theatre 1 titled “Where’s the Money? Evolution And Future Outlook for Investment in Advanced Therapies,” moderated by Sven Kili, Partner at Saisei Ventures. Rounding out the corporate presentations, Sr. Director of Regulatory Ananta Ayyagari will speak on filing global regulatory paperwork at 4:20 PM ET in Room 209.
Platform Technology Drives Retinal Disease Treatments
MOGENRY utilizes Nanoscope’s multi-characteristic opsin platform to deliver a proprietary synthetic opsin gene to dense bipolar retinal cells. The treatment is designed to make surviving cells directly light-sensitive following photoreceptor loss, allowing patients to utilize remaining visual circuitry without requiring genetic testing, invasive surgery, or repeat dosing.
Leber congenital amaurosis (LCA) is among the other IND-ready initiatives, while a Phase 2 trial focusing on MCO for geographic atrophy is anticipated to launch in 2026.
